These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28719177)

  • 41. Dopaminergic imaging: clinical utility now and in the future.
    Walker Z; Rodda J
    Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S32-40. PubMed ID: 21843378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Simulation-based partial volume correction for dopaminergic PET imaging: Impact of segmentation accuracy.
    Rong Y; Vernaleken I; Winz OH; Goedicke A; Mottaghy FM; Kops ER
    Z Med Phys; 2015 Sep; 25(3):230-42. PubMed ID: 25172832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.
    Ginovart N; Galineau L; Willeit M; Mizrahi R; Bloomfield PM; Seeman P; Houle S; Kapur S; Wilson AA
    J Neurochem; 2006 May; 97(4):1089-103. PubMed ID: 16606355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whatever happened to Pittsburgh Compound-A?
    Klunk WE; Mathis CA
    Alzheimer Dis Assoc Disord; 2008; 22(3):198-203. PubMed ID: 18769172
    [No Abstract]   [Full Text] [Related]  

  • 45. Sugar rush: the early days of molecular imaging.
    Ell PJ
    Lancet Oncol; 2008 Apr; 9(4):400. PubMed ID: 18374294
    [No Abstract]   [Full Text] [Related]  

  • 46. Quantitative PET analysis of the dopamine D2 receptor agonist radioligand 11C-(R)-2-CH3O-N-n-propylnorapomorphine in the human brain.
    Otsuka T; Ito H; Halldin C; Takahashi H; Takano H; Arakawa R; Okumura M; Kodaka F; Miyoshi M; Sekine M; Seki C; Nakao R; Suzuki K; Finnema S; Hirayasu Y; Suhara T; Farde L
    J Nucl Med; 2009 May; 50(5):703-10. PubMed ID: 19372485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging.
    Ko JH; Strafella AP
    Neuroscientist; 2012 Apr; 18(2):149-68. PubMed ID: 21536838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Posterior dopamine D2/3 receptors and brain network functional connectivity.
    Nagano-Saito A; Lissemore JI; Gravel P; Leyton M; Carbonell F; Benkelfat C
    Synapse; 2017 Nov; 71(11):. PubMed ID: 28700819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional imaging in primary headache disorders.
    Cutrer FM
    Headache; 2008 May; 48(5):704-6. PubMed ID: 18471116
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aging Affects Dopaminergic Neural Mechanisms of Cognitive Flexibility.
    Berry AS; Shah VD; Baker SL; Vogel JW; O'Neil JP; Janabi M; Schwimmer HD; Marks SM; Jagust WJ
    J Neurosci; 2016 Dec; 36(50):12559-12569. PubMed ID: 27807030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging.
    Arnaldi D; Morbelli S; Morrone E; Campus C; Nobili F
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):55-67. PubMed ID: 22460160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Positron emission tomography molecular imaging in late-life depression.
    Hirao K; Smith GS
    J Geriatr Psychiatry Neurol; 2014 Mar; 27(1):13-23. PubMed ID: 24394152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Molecular imaging of psychiatric disorders].
    Takahashi H; Suhara T
    Nihon Rinsho; 2007 Feb; 65(2):336-41. PubMed ID: 17302281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders.
    Royse SK; Lopresti BJ; Mathis CA; Tollefson S; Narendran R
    J Neurochem; 2023 Feb; 164(3):401-443. PubMed ID: 35716057
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome.
    Mille E; Levin J; Brendel M; Zach C; Barthel H; Sabri O; Bötzel K; Bartenstein P; Danek A; Rominger A
    J Neuroimaging; 2017 Mar; 27(2):255-261. PubMed ID: 27572945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Positron emission tomography and single-photon emission computed tomography in substance abuse research.
    Volkow ND; Fowler JS; Wang GJ
    Semin Nucl Med; 2003 Apr; 33(2):114-28. PubMed ID: 12756644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.
    de Vries EF; Kortekaas R; van Waarde A; Dijkstra D; Elsinga PH; Vaalburg W
    J Nucl Med; 2005 Aug; 46(8):1384-92. PubMed ID: 16085598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural neuroimaging in neuropsychology: History and contemporary applications.
    Bigler ED
    Neuropsychology; 2017 Nov; 31(8):934-953. PubMed ID: 29376671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status of positron emission tomography radiotracers for serotonin receptors in humans.
    Zimmer L; Le Bars D
    J Labelled Comp Radiopharm; 2013; 56(3-4):105-13. PubMed ID: 24285316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential.
    Mercer JR
    J Pharm Pharm Sci; 2007; 10(2):180-202. PubMed ID: 17706177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.